Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine

              Author:Croop, Robert   Madonia, Jennifer   Hould, Jennifer   Mosher, Linda   Lovegren, Meghan   Lipton, Richard   

              Session Name:P9: Headache: The Gepant Pipeline  

              Topic:Headache  

              Program Number:P9.002  

              Author Institution:Biohaven Pharmaceuticals, Wynnewood, PA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Wallingford, CT  Albert Einstein College of Medicine, Bronx, NY  

              Long-Term Safety and Tolerability of Zavegepant 10 mg Nasal Spray During Concomitant Use of CGRP Monoclonal Antibodies: Results From a 1-Year Open-label Safety Trial

              Author:Berman, Gary   Mullin, Kathleen   Pavlovic, Jelena   Smith, Timothy   Croop, Robert   Madonia, Jennifer   Mosher, Linda   Hould, Jennifer   Lipton, Richard   

              Session Name:P10: Headache: Towards Precision Medicine 1  

              Topic:Headache  

              Program Number:P10.009  

              Author Institution:Clinical Research Institute , Minneapolis, MN  New England Institute for Neurology and Headache, Stamford, CT  Albert Einstein College of Medicine, Bronx, NY  StudyMetrix Research, Saint Louis, MO  Biohaven Pharmaceuticals, Wynnewood, PA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Wallingford, CT